UNSPSC 51434810: Mazokalim

This classification denotes an antihypertensive agent with the molecular formula C23H28N6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K3N608EC7L, chemically known as ethyl 5-((3s,4r)-4-((1,6-dihydro-6-oxo-3-pyridazinyl)oxy)-3-hydroxy-2,2,3-trimethyl-6-chromanyl)-1h-tetrazole-1-butyrate. but generally known as mazokalim, which bears US NIH Compound Identifier 3045404. European Medicines Agency schedules Mazokalim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08658MIG.

UNSPSC 51434810 Mazokalim is a Commodity code under which state and local governments procure emergency-response and acute-care pharmaceuticals—specifically injectable medications for advanced life support protocols. Recent solicitations show state and local buyers sourcing individual medication line items (epinephrine, labetalol, adenosine, diltiazem) for fire-rescue and emergency medical services, as well as broader generic and over-the-counter pharmaceutical inventories through cooperative purchasing arrangements. The work ranges from single-jurisdiction sealed bids for discrete medication orders with defined unit quantities and expiration requirements to multistate cooperative purchasing programs that aggregate pharmaceutical sourcing across participating state agencies and local government facilities. Issuing bodies include municipal fire-rescue departments (operating under city purchasing offices), state health agencies, and multistate purchasing alliances coordinating procurement for state and local member jurisdictions.

Recent activity appears concentrated in the South and Upper Midwest. The City of Tampa Purchasing Department solicited Advanced Life Support Medications (Bid No. 26-P-00188) as a sealed bid due April 8, 2026, for use by Tampa Fire Rescue in Hillsborough County, Florida, with an estimated contract value of $40,000.00 and a one-year term plus renewal options; the bid carried a 5 percent Small Local Business Enterprise (SLBE) discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products due March 26, 2026, requiring vendors to supply through three authorized wholesalers with a contract term of two years effective July 1, 2026. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in late March 2026 exploring vendor capabilities for direct-to-manufacturer prescription programs, indicating emerging state interest in alternative pharmacy benefit delivery models. Geographic spread covers Florida, Minnesota, Oregon (through MMCAP membership), and Texas.